From multiple hits to multiple therapeutic targets of non-alcoholic fatty liver disease

Current Drug Targets

Volumn 16, Issue 12, 2015, Pages 1272-1273

  Zhu, Lixin ^a   Baker, Robert D ^a   Baker, Susan S ^a  

^a UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN 17; PIOGLITAZONE;

DISEASE COURSE; EDITORIAL; ENDOPLASMIC RETICULUM STRESS; FATTY ACID OXIDATION; FATTY LIVER; HISTOLOGY; HUMAN; INFLAMMATION; INNATE IMMUNITY; INSULIN RESISTANCE; LIPID METABOLISM; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; OBESITY; OXIDATIVE STRESS; PREVALENCE; SIGNAL TRANSDUCTION; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOPHYSIOLOGY;

HUMANS; NON-ALCOHOLIC FATTY LIVER DISEASE;

EID: 84946736249     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116999150928154553     Document Type: Editorial

References (16)

1. [1] Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011; 141(4): 1249-53.
2. [2] McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. J Hepatol 2015; 62(5): 1148-55.
3. [3] Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liverrelated mortality. Hepatology 2011; 53(6): 1874-82.
4. [4] Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52(1): 79-104.
5. [5] Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010; 52(5): 1836-46.
6. [6] Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362(18): 1675-85.
7. [7] Neuschwander-Tetri BA, Loomba R, Sanyal AJ, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015; 385(9972): 956-65.
8. [8] Forte TM, Ryan RO. Apolipoprotein A5: extracellular and intracellular roles in triglyceride metabolism. Curr Drug Targets 2015; 16(12): 1274-80.
9. [9] Zhu L, Baker SS, Liu W, et al. Lipid in the livers of adolescents with nonalcoholic steatohepatitis: combined effects of pathways on steatosis. Metabolism 2011; 60(7): 1001-11.
10. [10] Chen G. The link between hepatic vitamin A homeostasis and nonalcoholic fatty liver disease. Curr Drug Targets 2015; 16(12): 1281-92.
11. [11] Kawano Y, Nishiumi S, Saito M, Yano Y, Azuma T, Yoshida M. Identification of lipid species linked to the progression of non-alcoholic fatty liver disease. Curr Drug Targets 2015; 16(12): 1293-1300.
12. [12] Liu W, Baker SS, Baker RD, Zhu L. Antioxidant mechanisms in nonalcoholic fatty liver disease. Curr Drug Targets 2015; 16(12): 1301-14.
13. [13] Giles DA, Moreno-Fernandez ME, Divanovic S. IL-17 axis driven inflammation in non-alcoholic fatty liver disease progression. Curr Drug Targets 2015; 16(12): 1315-23.
14. [14] Mouzaki M, Bandsma R. Targeting the gut microbiota for the treatment of non-alcoholic fatty liver disease. Curr Drug Targets 2015; 16(12): 1324-31.
15. [15] Pritchard MT, McCracken JM. Identifying novel targets for treatment of liver fibrosis: what can we learn from injured tissues which heal without a scar? Curr Drug Targets 2015; 16(12): 1332-46.
16. [16] Xu JY, Zhang L, Li ZP, Ji G. Natural products on nonalcoholic fatty liver disease. Curr Drug Targets 2015; 16(12): 1347-55.